Search

Liudmila Kulik

age ~60

from Aurora, CO

Liudmila Kulik Phones & Addresses

  • 14934 E Hampden Cir APT D5, Aurora, CO 80014 • 7203897612
  • Denver, CO
  • 14934 E Hampden Cir APT D5, Aurora, CO 80014

Us Patents

  • Antibodies To The C3D Fragment Of Complement Component 3

    view source
  • US Patent:
    20130078245, Mar 28, 2013
  • Filed:
    Aug 17, 2012
  • Appl. No.:
    13/589079
  • Inventors:
    V. Michael Holers - Denver CO, US
    Joshua M. Thurman - Greenwood CO, US
    Liudmila Kulik - Aurora CO, US
  • Assignee:
    The Regents of the University of Colorado, a body Corporate - Boulder CO
  • International Classification:
    C07K 16/18
    C07K 14/47
  • US Classification:
    4241341, 5303893, 5303873, 53038825, 4241581
  • Abstract:
    The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting prophylactic or therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.
  • Antibodies To The C3D Fragment Of Complement Component 3

    view source
  • US Patent:
    20130129728, May 23, 2013
  • Filed:
    Jun 22, 2011
  • Appl. No.:
    13/805522
  • Inventors:
    V. Michael Holers - Denver CO, US
    Joshua M. Thurman - Greenwood Village CO, US
    Liudmila Kulik - Aurora CO, US
  • Assignee:
    The Regents of the University of Colorado, a Body Corporate - Denver CO
  • International Classification:
    C07K 16/18
  • US Classification:
    4241341, 5303898, 5303873, 5303882, 435332, 536 2353, 4353201, 435 696, 4241721, 435328, 4352523, 4352542, 435419, 43525233, 43525421, 43525423
  • Abstract:
    The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.
  • Prevention And Treatment Of Ischemia-Reperfusion Injury And Related Conditions

    view source
  • US Patent:
    20130171236, Jul 4, 2013
  • Filed:
    Aug 21, 2012
  • Appl. No.:
    13/591181
  • Inventors:
    Vernon Michael Holers - Denver CO, US
    Liudmila Kulik - Aurora CO, US
    George C. Tsokos - Silver Springs MD, US
    Stephen Tomlinson - Mount Pleasant SC, US
  • Assignee:
    MEDICAL UNIVERSITY OF SOUTH CAROLINA - Charleston SC
    THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate - Denver CO
  • International Classification:
    A61K 38/17
    A61K 31/685
    A61K 9/127
  • US Classification:
    424450, 514 151, 514 78
  • Abstract:
    Disclosed are lipids, annexin, and lipid-annexin complexes for use in the prevention and/or treatment of ischemia-reperfusion injury and reperfusion injury associated with a variety of diseases and conditions. Also disclosed are therapeutic targets and compositions for the prevention and treatment of ischemia-reperfusion injury and diseases and conditions associated with ischemia-reperfusion injury.
  • Prevention And Treatment Of Ischemia-Reperfusion Injury And Related Conditions

    view source
  • US Patent:
    20110014270, Jan 20, 2011
  • Filed:
    Mar 27, 2007
  • Appl. No.:
    12/294870
  • Inventors:
    Vernon Michael Holers - Denver CO, US
    Liudmila Kulik - Aurora CO, US
    George C. Tsokos - Silver Springs MD, US
    Stephen Tomlinson - Mount Pleasant SC, US
  • Assignee:
    THE REGENTS OF THE UNIVERSITY OF COLORADO - Denver CO
  • International Classification:
    A61K 9/127
    A61K 38/16
    A61K 39/395
    C07K 16/00
    C07K 14/00
    A61P 9/10
    A61P 13/12
    A61P 25/00
    A61P 37/06
  • US Classification:
    424450, 514 151, 4241721, 5303891, 530402
  • Abstract:
    Disclosed are Lipids, Annexin, and Lipid-Annexin Complexes for Use in the Prevention and/or Treatment of Ischemia-Reperfusion injury and reperfusion injury associated with a variety of diseases and conditions. Also disclosed are therapeutic targets and compositions for the prevention and treatment of ischemia-reperfusion injury and diseases and conditions associated with ischemia-reperfusion injury.
  • Targeting Constructs Based On Natural Antibodies And Uses Thereof

    view source
  • US Patent:
    20210388080, Dec 16, 2021
  • Filed:
    Apr 12, 2021
  • Appl. No.:
    17/228279
  • Inventors:
    - Denver CO, US
    - Charleston SC, US
    - Washington DC, US
    Joshua M. Thurman - Greenwood Village CO, US
    Carl Atkinson - Mount Pleasant SC, US
    Liudmila Kulik - Aurora CO, US
  • International Classification:
    C07K 16/28
    A61K 39/395
    A61K 45/06
  • Abstract:
    The present invention provides targeted delivery methods and constructs for treating inflammatory diseases and/or detecting in vivo tissue injuries in an individual. The targeted delivery approach utilizes an antibody that recognizes an epitope found to be present at sites of inflammation. The invention also provides methods of inhibiting complement-driven inflammation in the eye in an individual, comprising administering to the individual an antibody or a fragment thereor or compositions thereof, wherein the antibody or fragment thereof specifically binds to Annexin IV or phospholipid. Also provided are related methods of treating a complement-associated ocular disease or an ocular disease involving oxidative damage. Additionally, the invention provides methods of detecting complement-mediated injury in an eye tissue of an individual, comprising administering to the individual a construct or compositions thereof, wherein the construct comprises (a) an antibody or fragment thereof that specifically binds to Annexin IV or phospholipid; and (b) a detectable moiety.
  • Map44 Polypeptides And Constructs Based On Natural Antibodies And Uses Thereof

    view source
  • US Patent:
    20210213110, Jul 15, 2021
  • Filed:
    Dec 7, 2020
  • Appl. No.:
    17/113612
  • Inventors:
    - Denver CO, US
    Nirmal Banda - Aurora CO, US
    Liudmila Kulik - Denver CO, US
  • Assignee:
    The Regents of The University of Colorado, A Body Corporate - Denver CO
  • International Classification:
    A61K 38/48
    A01K 67/027
    C07K 16/18
    C07K 16/44
    C12N 9/64
  • Abstract:
    The present invention provides delivery methods and constructs for treating inflammatory diseases in an individual. The targeted delivery approach utilizes an antibody that recognizes an epitope found to be present at sites of inflammation. The antibody is used to deliver a MAp44 polypeptide or fragment thereof to sites of inflammation, where it inhibits the lectin pathway of complement activation.
  • Map44 Polypeptides And Constructs Based On Natural Antibodies And Uses Thereof

    view source
  • US Patent:
    20170209549, Jul 27, 2017
  • Filed:
    Jun 4, 2015
  • Appl. No.:
    15/316113
  • Inventors:
    - Denver CO, US
    Nirmal Banda - Aurora CO, US
    Liudmila Kulik - Denver CO, US
  • International Classification:
    A61K 38/48
    C07K 16/44
    C07K 16/18
    C12N 9/64
  • Abstract:
    The present invention provides delivery methods and constructs for treating inflammatory diseases in an individual. The targeted delivery approach utilizes an antibody that recognizes an epitope found to be present at sites of inflammation. The antibody is used to deliver a MAp44 polypeptide or fragment thereof to sites of inflammation, where it inhibits the lectin pathway of complement activation.
  • Targeting Constructs Based On Natural Antibodies And Uses Thereof

    view source
  • US Patent:
    20160083469, Mar 24, 2016
  • Filed:
    Jul 23, 2015
  • Appl. No.:
    14/807521
  • Inventors:
    - Denver CO, US
    - Charleston SC, US
    - Washington DC, US
    Joshua M. Thurman - Greenwood Village CO, US
    Carl Atkinson - Mount Pleasant SC, US
    Liudmila Kulik - Aurora CO, US
  • International Classification:
    C07K 16/28
    A61K 45/06
    A61K 39/395
  • Abstract:
    The present invention provides targeted delivery methods and constructs for treating inflammatory diseases and/or detecting in vivo tissue injuries in an individual. The targeted delivery approach utilizes an antibody that recognises an epitope found to be present at sites of inflammation. The invention also provides methods of inhibiting complement-driven inflammation in the eye in an individual, comprising administering to the individual an antibody or a fragment thereof or compositions thereof, wherein the antibody or fragment thereof specifically binds to Annexin IV or phospholipid. Also provided are related methods of treating a complement-associated ocular disease or an ocular disease involving oxidative damage. Additionally, the invention provides methods of detecting complement-mediated injury in an eye tissue of an individual, comprising administering to the individual a construct or compositions thereof, wherein the construct comprises (a) an antibody or fragment thereof that specifically binds to Annexin IV or phospholipid; and (b) a detectable moiety.

Get Report for Liudmila Kulik from Aurora, CO, age ~60
Control profile